Progress on treatment of MET signaling pathway in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-020-01702-0
Abstract: MET activation includes gene mutation, amplification, and protein overexpression. Clinical evidence suggests that MET activation is both a primary oncogenic driver in lung cancer, and a secondary driver after acquired resistance to EGFR tyrosine kinase… read more here.
Keywords: treatment met; progress treatment; lung cancer; met signaling ... See more keywords